BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
47.37
+0.10 (0.21%)
At close: Aug 1, 2025, 4:00 PM
46.91
-0.46 (-0.97%)
After-hours: Aug 1, 2025, 7:48 PM EDT
Accolade Employees
As of December 31, 2024, BridgeBio Pharma had 730 total employees, including 725 full-time and 5 part-time employees. The number of employees increased by 174 or 31.29% compared to the previous year.
Employees
730
Change (1Y)
174
Growth (1Y)
31.29%
Revenue / Employee
$174,541
Profits / Employee
-$915,025
Market Cap
8.99B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 730 | 174 | 31.29% |
| Dec 31, 2023 | 556 | 160 | 40.40% |
| Dec 31, 2022 | 396 | -182 | -31.49% |
| Dec 31, 2021 | 578 | 182 | 45.96% |
| Dec 31, 2020 | 396 | 148 | 59.68% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BBIO News
- 2 days ago - Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains. - Barrons
- 9 days ago - Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1 - GlobeNewsWire
- 10 days ago - BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET - GlobeNewsWire
- 4 weeks ago - BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty - GlobeNewsWire
- 5 weeks ago - BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET - GlobeNewsWire
- 2 months ago - BridgeBio: New Data Bolsters The Bull Case - Seeking Alpha
- 2 months ago - BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - GlobeNewsWire
- 2 months ago - Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM - GlobeNewsWire